Every 10-Q that Abbott Labs (ABT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ABT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ABT filings page.
Abbott Laboratories filed its Q3 2025 report with steady profit and higher sales. Net sales were $11,369 million, up from $10,635 million a year ago, while diluted EPS held at $0.94. Year‑to‑date, sales reached $32,869 million and diluted EPS rose to $2.70 from $2.38. Operating earnings improved to $2,057 million, supported by Medical Devices growth (notably Diabetes Care and Electrophysiology) and stronger Established Pharmaceuticals, partly offset by lower COVID‑19 testing revenue.
Cash from operations was $6,251 million for the first nine months, funding $1,503 million of long‑term debt repayments and $3,086 million in dividends, with purchases of common shares of $591 million. The company recorded 2025 restructuring charges of $197 million and $25 million of asset impairments to streamline diagnostics and devices. Remaining performance obligations were $6.0 billion in Diagnostics and $436 million in Medical Devices. As of September 30, 2025, common shares outstanding were 1,738,871,947.